메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색
질문

논문 기본 정보

자료유형
학술저널
저자정보
Attada Tharun (Koneru Lakshmaiah Education Foundation) Potnuru Jagadeesh (Koneru Lakshmaiah Education Foundation) B Srinivasa Kumar (Koneru Lakshmaiah Education Foundation) Kota Thirumala Prasad (PSCMR College of Engineering and Technology) Venkateswara Rao Anna (Koneru Lakshmaiah Education Foundation)
저널정보
한국분석과학회 분석과학 분석과학 제36권 제4호
발행연도
2023.8
수록면
180 - 190 (11page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색
질문

초록· 키워드

오류제보하기
The presence of process related impurities in any drug or the drug product was associated with its safety, stability and efficacy. The overall literature survey proved that there is no method published on the assessment of process related impurities in brigatinib. In this study, a simple, reliable and stable HPLC qualitative method was reported for quantification of process related impurities with easy and quick extraction procedure. The impurities along with standard brigatinib was resolved on Lichrospher<SUP>®</SUP>C18 (250 mm × 4.6 mm; 5 μm particle size) column in room temperature using methanol, acetonitrile, pH 4.5 phosphate buffer in 55:25:20 (v/v) at 1.0 mL/min as mobile phase and UV detection at 261 nm. The method produces well resolved peaks at retention time of 4.60 min, 12.28 min, 3.37 min, 7.34 min and 8.39 min respectively for brigatinib, impurity A, B, C and D. The method produces a very sensitive detection limit of 0.0065 μg/mL, 0.0068 μg/mL, 0.0053 μg/mL and 0.0058 μg/mL for impurity A, B, C and D respectively with calibration curve linear in the concentration range of 22.5-135 μg/mL for brigatinib and 0.0225-0.135 μg/mL for impurities. The method produces all the validation parameters under the acceptable level and doesn’t produces any considerable changes in peak area response while minor changes in the developed method conditions. The method can effectively resolve the unknown stress degradation products along with known impurities with less % degradation. The method can efficiently resolve and quantify the impurities in formulation and hence can suitable for the routine quality analysis of brigatinib in raw material and formulation.

목차

Abstract
1. Introduction
2. Experimental
3. Results and Discussion
4. Conclusions
References

참고문헌 (18)

참고문헌 신청

이 논문의 저자 정보

이 논문과 함께 이용한 논문

최근 본 자료

전체보기

댓글(0)

0

UCI(KEPA) : I410-ECN-0102-2023-433-001946382